The treatment of acute myeloid leukemia in first relapse: a comprehensive review of the literature (Q35103330)

6 August 2017

1 reference

title

The treatment of acute myeloid leukemia in first relapse: a comprehensive review of the literature (English)

1 reference

6 August 2017

1 reference

acute myeloid leukemia

1 reference

Lance H Leopold

1

1 reference

6 August 2017

Roel Willemze

series ordinal

2

1 reference

6 August 2017

publication date

1 September 2002

1 reference

6 August 2017

1 reference

6 August 2017

volume

43

1 reference

6 August 2017

issue

9

1 reference

6 August 2017

page(s)

1715-1727

1 reference

6 August 2017

cites work

Acute myeloid leukemia

1 reference

https://api.crossref.org/works/10.1080%2F1042819021000006529

Management of acute myeloid leukemia in elderly patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1042819021000006529

Intensive postremission chemotherapy in adults with acute myeloid leukemia. Cancer and Leukemia Group B

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1042819021000006529

Randomised comparison of addition of autologous bone-marrow transplantation to intensive chemotherapy for acute myeloid leukaemia in first remission: results of MRC AML 10 trial. UK Medical Research Council Adult and Children's Leukaemia Working Par

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1042819021000006529

The characteristics and outcome of patients with late relapse acute myelogenous leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1042819021000006529

Multivariate analysis of prognostic factors in patients with refractory and relapsed acute myeloid leukemia undergoing sequential high-dose cytosine arabinoside and mitoxantrone (S-HAM) salvage therapy: relevance of cytogenetic abnormalities

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1042819021000006529

Principal results of the Medical Research Council's 8th acute myeloid leukaemia trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1042819021000006529

Response to salvage therapy and survival after relapse in acute myelogenous leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1042819021000006529

Results of Therapy for Acute Myeloid Leukemia in First Relapse

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1042819021000006529

Timed sequential chemotherapy for previously treated patients with acute myeloid leukemia: long-term follow-up of the etoposide, mitoxantrone, and cytarabine-86 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1042819021000006529

Fludarabine and arabinosylcytosine therapy of refractory and relapsed acute myelogenous leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1042819021000006529

Ceca–Cyclophosphamide, Etoposide, Carboplatin and Cytosine Arabinoside–A New Salvage Regimen for Relapsed or Refractory Acute Myelogenous Leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1042819021000006529

Combination of mitoxantrone and etoposide in refractory acute myelogenous leukemia--an active and well-tolerated regimen

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1042819021000006529

Fludarabine, cytarabine, and G-CSF (FLAG) for the treatment of acute myeloid leukemia relapsing after autologous stem cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1042819021000006529

Treatment of patients with recurrent and primary refractory acute myelogenous leukemia using mitoxantrone and intermediate-dose cytarabine: a pharmacologically based regimen

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1042819021000006529

Mitoxantrone, etoposide, and intermediate-dose cytarabine: an effective and tolerable regimen for the treatment of refractory acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1042819021000006529

Mitoxantrone for refractory and relapsed acute leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1042819021000006529

Synergy between high-dose cytarabine and asparaginase in the treatment of adults with refractory and relapsed acute myelogenous leukemia--a Cancer and Leukemia Group B Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1042819021000006529

4-Demethoxydaunorubicin (Idarubicin) in refractory or relapsed acute leukemias. A pilot study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1042819021000006529

Intermediate-dose cytosine arabinoside and amsacrine. An effective regimen with low toxicity in refractory acute nonlymphocytic leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1042819021000006529

High-dose cytosine arabinoside and L-asparaginase therapy for poor-risk adult acute nonlymphocytic leukemia. A retrospective study

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1042819021000006529

High-dose cytosine arabinoside therapy with and without anthracycline antibiotics for remission reinduction of acute nonlymphoblastic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1042819021000006529

High-dose cytosine arabinoside and m-AMSA is effective therapy in relapsed acute nonlymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1042819021000006529

Phase I-II clinical and pharmacologic studies of high-dose cytosine arabinoside in refractory leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1042819021000006529

A clinical and pharmacokinetic study of mitoxantrone in acute nonlymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1042819021000006529

The selective use of AMSA following high-dose cytarabine in patients with acute myeloid leukaemia in relapse: a Leukemia Intergroup study

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1042819021000006529

A phase II study of interleukin-2 in 49 patients with relapsed or refractory acute leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1042819021000006529

Fludarabine, cytarabine, and G-CSF (FLAG) for the treatment of poor risk acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1042819021000006529

Mitoxantrone and high-dose etoposide for patients with relapsed or refractory acute leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1042819021000006529

Sequential intermediate-dose cytosine arabinoside and mitoxantrone for patients with relapsed and refractory acute myelocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1042819021000006529

Low-dose cytosine arabinoside in patients with acute myeloid leukemia not eligible for standard chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1042819021000006529

Prediction of response of acute nonlymphocytic leukaemia to therapy with 'high dose' cytosine arabinoside.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1042819021000006529

High-dose cytarabine and recombinant human granulocyte colony-stimulating factor for the treatment of resistant acute myelogenous leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1042819021000006529

Phase I clinical and laboratory evaluation of topotecan and cytarabine in patients with acute leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1042819021000006529

Phase-II trial of idarubicin, fludarabine, cytosine arabinoside, and filgrastim (Ida-FLAG) for treatment of refractory, relapsed, and secondary AML.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1042819021000006529

Mitoxantrone, etoposide, and cytarabine plus cyclosporine for patients with relapsed or refractory acute myeloid leukemia: an Eastern Cooperative Oncology Group pilot study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1042819021000006529

2-Chlorodeoxyadenosine with or without daunorubicin in relapsed or refractory acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1042819021000006529

Mitoxantrone and high-dose cytosine arabinoside in refractory acute myelogenous leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1042819021000006529

FLAG (fludarabine, cytosine arabinoside, G-CSF) for refractory and relapsed acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1042819021000006529

10.1080/1042819021000006529

21 January 2018

Identifiers

DOI

1 reference

6 August 2017

1 reference